Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

JAMA. 1999 Aug 25;282(8):786-90. doi: 10.1001/jama.282.8.786.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Biomarkers
  • Cardiovascular Agents* / therapeutic use
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / prevention & control*
  • Clinical Trials as Topic*
  • Drug Approval*
  • Humans
  • Risk
  • Risk Factors
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Biomarkers
  • Cardiovascular Agents